Pulmonary Delivery of Spray-Dried Monoclonal Antibody Formulations
Content Type: Whitepaper/Executive Summary
Authors: Kimberly Shepard
Publish Date: 5/13/2021
In the case study presented here, spray drying was used to manufacture a dry-powder pulmonary formulation of bevacizumab, a monoclonal antibody approved to treat non-small-cell lung cancer (NSCLC) by intravenous infusion. By reformulating bevacizumab for local delivery, reduced side effects, lower doses, and improved patient compliance are possible. To learn more, please read our case study.